Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Dec 6, 3:05PM CST

APLS : 33.21 (+0.21%)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire - Wed Nov 27, 6:00AM CST

APLS : 33.21 (+0.21%)
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference GlobeNewswire - Tue Nov 12, 6:00AM CST

APLS : 33.21 (+0.21%)
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y Zacks Investment Research - Wed Nov 6, 11:46AM CST

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...

FOLD : 9.80 (+0.72%)
AVIR : 3.19 (+1.92%)
CRSP : 40.72 (+0.83%)
APLS : 33.21 (+0.21%)
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday Motley Fool - Tue Nov 5, 3:47PM CST

Sales of the company's top commercialized product didn't meet expectations.

$SPX : 5,930.85 (+1.09%)
APLS : 33.21 (+0.21%)
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results GlobeNewswire - Tue Nov 5, 6:05AM CST

APLS : 33.21 (+0.21%)
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst Motley Fool - Tue Oct 29, 4:51AM CDT

It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.

BAC : 44.17 (+1.82%)
ALPMY : 9.7900 (+1.45%)
APLS : 33.21 (+0.21%)
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN GlobeNewswire - Sat Oct 26, 1:00PM CDT

APLS : 33.21 (+0.21%)
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results GlobeNewswire - Tue Oct 22, 6:00AM CDT

APLS : 33.21 (+0.21%)
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN GlobeNewswire - Wed Oct 16, 6:00AM CDT

APLS : 33.21 (+0.21%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot